Literature DB >> 2142343

Specific elimination of alloreactive T cells by an anti-interleukin-2 receptor B chain-specific immunotoxin.

M Cavazzana-Calvo1, C Fromont, F Le Deist, M Lusardi, L Coulombel, J M Derocq, I Gerota, C Griscelli, A Fischer.   

Abstract

Graft-versus-host disease and graft rejection remain the two principal causes of morbidity and mortality after major-histocompatibility-complex-mismatched bone marrow transplantation. Human and animal models suggest that both CD4+ and CD8+ T cell subsets present in the donor inoculum are responsible for their initiation. Since the human mixed lymphocyte culture (MLC) and the HLA-restricted cytotoxicity may reflect cellular interactions occurring during GVHD and graft rejection, inhibitions of these responses may represent useful approaches for screening functional T cell depletion in experimental bone marrow transplantation studies. For this purpose, we have tested the possibility of removing the host-specific allogeneic T cells present in the marrow. After a two-day MLC, the specifically activated host alloreactive blood or bone marrow T cells were incubated with the ricin A-chain toxin conjugated with the antibody 33B3.1 directed against the human receptor of interleukin 2 (33B3.1-IT). A complete inhibition of a primary MLC and of cytotoxic activities was observed as well as a disappearance of IL-2R(+) (p55) T cells. This method had limited consequence upon the alloreactivity of blood or marrow T cells toward a third unrelated party. The limiting-dilution analysis of residual alloantigen-reactive T lymphocytes has shown that this depletion results in a twentyfold to fiftyfold reduction of antihost reactivity. The procedure was also shown not to inhibit the growth of marrow precursors for granulocytes and macrophages.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2142343     DOI: 10.1097/00007890-199007000-00001

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  15 in total

1.  Blocked ricin-conjugated T cell immunotoxins: effect of anti-CD6-blocked ricin on normal T cell function.

Authors:  R A Rasmussen; S L Counts; J M Lambert; A R Collinson
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

2.  Selective depletion of alloreactive donor lymphocytes: a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation.

Authors:  Scott R Solomon; Stephan Mielke; Bipin N Savani; Aldemar Montero; Laura Wisch; Richard Childs; Nancy Hensel; John Schindler; Victor Ghetie; Susan F Leitman; Thao Mai; Charles S Carter; Roger Kurlander; Elizabeth J Read; Ellen S Vitetta; A John Barrett
Journal:  Blood       Date:  2005-04-07       Impact factor: 22.113

3.  CD134-allodepletion allows selective elimination of alloreactive human T cells without loss of virus-specific and leukemia-specific effectors.

Authors:  Xupeng Ge; Julia Brown; Megan Sykes; Vassiliki A Boussiotis
Journal:  Biol Blood Marrow Transplant       Date:  2008-05       Impact factor: 5.742

Review 4.  Current and emerging strategies for the prevention of graft-versus-host disease.

Authors:  Sung Won Choi; Pavan Reddy
Journal:  Nat Rev Clin Oncol       Date:  2014-06-24       Impact factor: 66.675

5.  Expansion of allospecific regulatory T cells after anergized, mismatched bone marrow transplantation.

Authors:  Jeffrey K Davies; Lee M Nadler; Eva C Guinan
Journal:  Sci Transl Med       Date:  2009-10-07       Impact factor: 17.956

6.  Combining CD19 redirection and alloanergization to generate tumor-specific human T cells for allogeneic cell therapy of B-cell malignancies.

Authors:  Jeff K Davies; Harjeet Singh; Helen Huls; Dongin Yuk; Dean A Lee; Partow Kebriaei; Richard E Champlin; Lee M Nadler; Eva C Guinan; Laurence J N Cooper
Journal:  Cancer Res       Date:  2010-04-27       Impact factor: 12.701

7.  Attenuation of GVHD for allo-bone marrow transplantation recipient by FasL-Fas pathway in an H-2 haplotype disparate mouse combination.

Authors:  Lingbo Liu; Ping Zou; Zhongbo Hu; Zhaodong Zhong; Juan Xiao; Rong Guo; Zhiliang Xu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2004

8.  Reconstitution of FOXP3+ regulatory T cells (Tregs) after CD25-depleted allotransplantation in elderly patients and association with acute graft-versus-host disease.

Authors:  Stephan Mielke; Katayoun Rezvani; Bipin N Savani; Raquel Nunes; Agnes S M Yong; John Schindler; Roger Kurlander; Victor Ghetie; Elizabeth J Read; Scott R Solomon; Ellen S Vitetta; A John Barrett
Journal:  Blood       Date:  2007-05-03       Impact factor: 22.113

9.  Selective reduction of graft-versus-host disease-mediating human T cells by ex vivo treatment with soluble Fas ligand.

Authors:  Osnat Bohana-Kashtan; Sebastien Morisot; Richard Hildreth; Cory Brayton; Hyam I Levitsky; Curt I Civin
Journal:  J Immunol       Date:  2009-06-17       Impact factor: 5.422

10.  Outcome of alloanergized haploidentical bone marrow transplantation after ex vivo costimulatory blockade: results of 2 phase 1 studies.

Authors:  Jeff K Davies; John G Gribben; Lisa L Brennan; Dongin Yuk; Lee M Nadler; Eva C Guinan
Journal:  Blood       Date:  2008-07-10       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.